Aluminium hydroxide versus sucralfate as a phosphate binder in uraemia.
- 30 April 1983
- Vol. 286 (6375) , 1379-1381
- https://doi.org/10.1136/bmj.286.6375.1379
Abstract
In an attempt to discover a phosphate binding agent for use in uraemia that would not lead to appreciable systemic absorption of aluminium the effect of sucralfate was evaluated after three weeks and compared with that of the existing standard agent aluminium hydroxide. Sucralfate caused a decrease in serum phosphate concentration comparable with that obtained with aluminium hydroxide, but similar absorption of aluminium resulted. Sucralfate may be the phosphate binder of choice in patients with uraemia and peptic ulceration; care should be taken in using large doses of the drug in patients with normal renal function.This publication has 15 references indexed in Scilit:
- ACUTE ALUMINIUM INTOXICATION IN PATIENTS ON CONTINUOUS AMBULATORY PERITONEAL DIALYSISThe Lancet, 1982
- Efficacy of sucralfate for duodenal ulcers: a multicenter, double-blind trial.1981
- Serum Aluminum and Continuous Ambulatory Peritoneal DialysisAnnals of Internal Medicine, 1980
- Aluminium toxicity during regular haemodialysis.BMJ, 1978
- BRAIN-ALUMINIUM CONCENTRATION IN DIALYSIS ENCEPHALOPATHYThe Lancet, 1978
- OSTEOMALACIC DIALYSIS OSTEODYSTROPHY: EVIDENCE FOR A WATER-BORNE ÆTIOLOGICAL AGENT, PROBABLY ALUMINIUMThe Lancet, 1978
- Composition of the domestic water supply and the incidence of fractures and encephalopathy in patients on home dialysis.BMJ, 1977
- Gastrointestinal Absorption of Aluminum from Aluminum-Containing AntacidsNew England Journal of Medicine, 1977
- The Dialysis Encephalopathy SyndromeNew England Journal of Medicine, 1976
- HYPERALUMINqMIA FROM ALUMINIUM RESINS IN RENAL FAILUREThe Lancet, 1970